Vascepa

Why Amarin Shares Are Plunging

Amarin Reports Mixed Q2 As COVID-19 Weighs On Results; Analyst Sees Favorable Risk-Reward

Amarin Analysts Say Vascepa Patent Settlement Not A Stock Mover, With 'Little Readthrough For Pending Patent Appeal'

Amarin Reports Mixed Q2 As COVID-19 Weighs On Results; Analyst Sees Favorable Risk-Reward

Amarin Analysts Say Vascepa Patent Settlement Not A Stock Mover, With 'Little Readthrough For Pending Patent Appeal'

Generic Threat To Amarin's Vascepa Overrides Positive Sentiment On Coronavirus Announcement

Amarin Analysts React To Vascepa Patent Loss, See Small Chance Of Overturning Judgment

Generic Threat To Amarin's Vascepa Overrides Positive Sentiment On Coronavirus Announcement

Amarin Analysts React To Vascepa Patent Loss, See Small Chance Of Overturning Judgment

The Daily Biotech Pulse: Amarin Faces Legal Setback, Milestone Payment Kicks In For CytomX, Savara, Reata Disclose COVID-19 Disruptions

Amarin Shares Drop 67% As Court Invalidates Its Heart Drug Patent For Vascepa

Vascepa Recent News

PreMarket Prep Stock Of The Day: Amarin

After Amarin Snags Vascepa Label Expansion, Analyst Says Biopharma An Attractive M&A Target

Analyst: Peak Sales Potential Of Amarin's Vascepa Underappreciated

Amarin's Vascepa Adcom Meeting: What You Need To Know

Amarin Shares Climb Following In-Line Review Of Fish Oil Pill By FDA Staffers

Amarin Shares Topple On Adcom Meeting Surprise For Fish Oil Pill

Amarin's Cardiovascular Fish Oil Pill May Hit Market Sooner: FDA Accords Priority Review Designation

Amarin Rallies After Diabetes Association Adds Fish Oil Capsule To Standards of Care List

Amarin Reports Encouraging Data, Vascepa Shows 30% Reduction In Total Cardiovascular Events In REDUCE-IT Study

Amarin Trades Down After Release Of Late-Stage Vascepa Trial Results

Analyst: Amarin's Vascepa Results Create Unicorn Potential, M&A Opportunity

Amarin Shares Skyrocket On Positive Cardio Trial Results

Amarin Soars After Vascepa Settlement

EXCLUSIVE: Expect Amarin FAQ Shortly

Amarin's Vascepa: Too Limited A Market Or FDA Blunder?

Trading in Amarin Muted After Thursday's After Hours Massacre